Enfortumab vedotin for cisplatin-ineligible urothelial cancer Comment

被引：1
作者：
Pignot, Geraldine [1 ]
机构：
[1] Inst Paoli Calmettes, Dept Surg Oncol 2, F-13009 Marseille, France
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 06期
关键词：
D O I：
10.1016/S1470-2045(21)00142-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：748 / 749
页数：2
相关论文
共 8 条
  • [1] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
  • [2] Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy
    Galsky, Matthew D.
    Hahn, Noah M.
    Rosenberg, Jonathan
    Sonpavde, Guru
    Hutson, Thomas
    Oh, William K.
    Dreicer, Robert
    Vogelzang, Nicholas
    Sternberg, Cora N.
    Bajorin, Dean F.
    Bellmunt, Joaquim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2432 - 2438
  • [3] Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer
    Le Goux, Constance
    Vacher, Sophie
    Schnitzler, Anne
    Delongchamps, Nicolas Barry
    Zerbib, Marc
    Peyromaure, Michael
    Sibony, Mathilde
    Allory, Yves
    Bieche, Ivan
    Damotte, Diane
    Pignot, Geraldine
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [4] Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
    Loriot, Y.
    Necchi, A.
    Park, S. H.
    Garcia-Donas, J.
    Huddart, R.
    Burgess, E.
    Fleming, M.
    Rezazadeh, A.
    Mellado, B.
    Varlamov, S.
    Joshi, M.
    Duran, I.
    Tagawa, S. T.
    Zakharia, Y.
    Zhong, B.
    Stuyckens, K.
    Santiago-Walker, A.
    De Porre, P.
    O'Hagan, A.
    Avadhani, A.
    Siefker-Radtke, A. O.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) : 338 - 348
  • [5] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    Powles, Thomas
    Rosenberg, Jonathan E.
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Wu, Chunzhang
    Campbell, Mary
    Matsangou, Maria
    Petrylak, Daniel P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12) : 1125 - 1135
  • [6] Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
    Rosenberg, Jonathan E.
    O'Donnell, Peter H.
    Balar, Arjun, V
    McGregor, Bradley A.
    Heath, Elisabeth, I
    Yu, Evan Y.
    Galsky, Matthew D.
    Hahn, Noah M.
    Gartner, Elaina M.
    Pinelli, Juan M.
    Liang, Shang-Ying
    Melhem-Bertrandt, Amal
    Petrylak, Daniel P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) : 2592 - +
  • [7] Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
    Vuky, Jacqueline
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean
    Hahn, Noah M.
    Savage, Mary J.
    Fang, Xiao
    Godwin, James Luke
    Frenkl, Tara L.
    Moreno, Blanca Homet
    de Wit, Ronald
    Plimack, Elizabeth R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2658 - +
  • [8] Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial
    Yu, Evan Y.
    Petrylak, Daniel P.
    O'Donnell, Peter H.
    Lee, Jae-Lyun
    van der Heijden, Michiel S.
    Loriot, Yohann
    Stein, Mark N.
    Necchi, Andrea
    Kojima, Takahiro
    Harrison, Michael R.
    Park, Se Hoon
    Quinn, David, I
    Heath, Elisabeth, I
    Rosenberg, Jonathan E.
    Steinberg, Joyce
    Liang, Shang-Ying
    Trowbridge, Janet
    Campbell, Mary
    McGregor, Bradley
    Balar, Arjun, V
    [J]. LANCET ONCOLOGY, 2021, 22 (06) : 872 - 882
1